Release Date: June 5, 2022
Expiration Date: June 29, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 4, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, and other HCPs involved in the treatment of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe efficacy and safety data of next-generation SERD agents for the management of HR+/HER2- breast cancer
- Explain how patient and tumoral characteristics can be aligned with clinical trial evidence to inform decision-making in the management of HR+/HER2- breast cancer
- Apply recent trial evidence to manage case scenarios typically encountered in HR+/HER2- breast cancer care and in consideration of evolving treatment paradigms in the field
- Determine ongoing trials concerning SERDs that are intended to address clinical gaps in the field of HR+/HER2- breast cancer management
Aditya Bardia, MD, MPH
Associate Professor
Harvard Medical School
Attending Physician, Medical Oncology
Massachusetts General Hospital
Boston, MA
Disclosures: Grant/Research Support: Daiichi Pharma/Astra Zeneca, Eli Lilly, Genentech, Immunomedics/Gilead, Merck, Novartis, Pfizer, Radius Health, Sanofi; Consultant: Daiichi Pharma/Astra Zeneca, Eli Lilly, Foundation Medicine, Genentech, Immunomedics/Gilead, Merck, Novartis, Pfizer, Philips, Radius Health, Sanofi.
Erika P. Hamilton, MD
Director
Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Disclosures: Grant/Research Support: ALL PAYMENTS TO INSTITUTION AbbVie, Acerta Pharma, ADC Therapeutics, Akesobio, Amgen, Aravive, ArQule Arvinas, AstraZeneca, Atlas Medx, Black Diamond Therapeutics, Boehringer lngelheim, Clovis Oncology, Compugen, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Deciphera, eFFECTOR Therapeutics, Ellipses Pharma, EMD Serono, Fochon, Fujifilm, G1 Therapeutics, H3 Biomedicine, Hutchison MediPharma, Immunogen, Immunomedics, Incyte, lnvestisBio, Jacobio, Karyopharm, Leap Therapeutics, Lilly, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Merck, Mersana, Merus, Millennium Pharmaceuticals, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema Pharmaceuticals, OncoMed, Onconova Therapeutics, Ori Biotech, Orinove, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr lmmunotherapeutics, Plexxikon, Radius Health, Regeneron, Repertoire Immune Medicines, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback, Stemcentrx, Sutro Biopharma, Syndax, Syros, Taiho Oncology, Tapimmune, Tesaro, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, Zymeworks; Consultant: Arcus, Arvinas AstraZeneca, Black Diamond Therapeutics, Boehringer lngelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo Oncology, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roche/Genentech, Seagen, Silverback Therapeutics.
Komal Jhaveri, MD, FACP
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: AstraZeneca, Genentech, Immunomedics/Gilead, Novartis, Lilly Pharmaceuticals/Loxo Oncology, Merck/VelosBio, Novartis, Pfizer, Puma Biotechnology, Zymeworks; Consultant: AbbVie, AstraZeneca, Blueprint Medicines, Biotheranostics, Genentech, Lilly Pharmaceuticals/Loxo Oncology, Novartis, Pfizer, Seagen, Sun Pharma Pvt Ltd, Taiho Oncology.
Nicholas Turner, MD, PhD
Academic Consultant
Medical Oncologist
Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, England, UK
Disclosures: Grant/Research Support: AstraZeneca, BioRad, Pfizer, Roche/Genentech, Merck Sharpe and Dohme, Guardant Health, Invitae, Inivata, Personalis, Natera; Consultant: AstraZeneca, Bristol Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, GaxoSmithKline, Zentalis Pharmaceuticals, Repare Therapeutics, Arvinas, Inivata.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
